Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a common …

Dive Brief: Johnson & Johnson is partnering with Remix Therapeutics to develop drugs that are meant to reprogram how RNA is processed, becoming the latest …

Double-digit list price increases for branded medicines in the middle of the last decade put drugmakers in political crosshairs. Under criticism and pressure, those boosts …

Though drugmakers have spent considerable resources trying to expand the reach of immunotherapy through new drug combinations, success has been hard to find. Multiple high-profile …

Lengo’s drug targets a mutation in the gene that drives production of a protein called EGFR, which, in turn, can help spur tumor growth. The …

Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant. Facing a coronavirus variant that experts …

Atea’s fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. …

When drugmakers geared up to respond to the pandemic, Sanofi and GSK, as two of the largest vaccine makers, were expected to make a major …

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. …

The FDA’s decision wasn’t surprising to analysts, as “deficiencies” in an approval application have become somewhat of a prelude to rejection. This year alone saw …

Drugmakers have laboured for decades to successfully develop a vaccine to protect infants and older people against infections of a common pathogen called respiratory syncytial …